Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2020 Oct 22:371:m3939.
doi: 10.1136/bmj.m3939.

Convalescent plasma in the management of moderate covid-19 in adults in India: open label phase II multicentre randomised controlled trial (PLACID Trial)

Anup Agarwal  1 , Aparna Mukherjee  2 , Gunjan Kumar  1 , Pranab Chatterjee  1 , Tarun Bhatnagar  3 , Pankaj Malhotra  4 ; PLACID Trial Collaborators
Collaborators, Affiliations
Clinical Trial

Convalescent plasma in the management of moderate covid-19 in adults in India: open label phase II multicentre randomised controlled trial (PLACID Trial)

Anup Agarwal et al. BMJ. .

Erratum in

Abstract

Objective: To investigate the effectiveness of using convalescent plasma to treat moderate coronavirus disease 2019 (covid-19) in adults in India.

Design: Open label, parallel arm, phase II, multicentre, randomised controlled trial.

Setting: 39 public and private hospitals across India.

Participants: 464 adults (≥18 years) admitted to hospital (screened 22 April to 14 July 2020) with confirmed moderate covid-19 (partial pressure of oxygen in arterial blood/fraction of inspired oxygen (PaO2/FiO2) ratio between 200 mm Hg and 300 mm Hg or a respiratory rate of more than 24/min with oxygen saturation 93% or less on room air): 235 were assigned to convalescent plasma with best standard of care (intervention arm) and 229 to best standard of care only (control arm).

Interventions: Participants in the intervention arm received two doses of 200 mL convalescent plasma, transfused 24 hours apart. The presence and levels of neutralising antibodies were not measured a priori; stored samples were assayed at the end of the study.

Main outcome measure: Composite of progression to severe disease (PaO2/FiO2 <100 mm Hg) or all cause mortality at 28 days post-enrolment.

Results: Progression to severe disease or all cause mortality at 28 days after enrolment occurred in 44 (19%) participants in the intervention arm and 41 (18%) in the control arm (risk difference 0.008 (95% confidence interval -0.062 to 0.078); risk ratio 1.04, 95% confidence interval 0.71 to 1.54).

Conclusion: Convalescent plasma was not associated with a reduction in progression to severe covid-19 or all cause mortality. This trial has high generalisability and approximates convalescent plasma use in real life settings with limited laboratory capacity. A priori measurement of neutralising antibody titres in donors and participants might further clarify the role of convalescent plasma in the management of covid-19.

Trial registration: Clinical Trial Registry of India CTRI/2020/04/024775.

PubMed Disclaimer

Conflict of interest statement

Competing interests: All authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf and declare that: TB is a member of the National Task Force for covid-19, which approved the protocol. AM, AA, GK, AT, TB, VS, KK, RS, SD, GD, SS, RG, AS, DP, CP, SS, KJ, HK, PDY, GS, PA, MM, and RMY are employed by the Indian Council of Medical Research (ICMR), the funding source for the trial. PC was an employee of ICMR during the trial.

Figures

Fig 1
Fig 1
Trial profile
Fig 2
Fig 2
Comparison of biomarkers between intervention (convalescent plasma therapy+best standard of care) and control (best standard of care) arms, by days post-enrolment. The dark line in the box represents the median and the upper and lower edges of the box represent the interquartile range. The upper and lower extreme of the whiskers represent the upper and lower range, respectively, excluding outliers
Fig 3
Fig 3
Comparison of neutralising antibody titres between intervention (convalescent plasma therapy and best standard of care and control (best standard of care) arms, by days 0, 3, and 7 post-enrolment
See this image and copyright information in PMC

Comment in

References

    1. Casadevall A, Joyner MJ, Pirofski LA. SARS-CoV-2 viral load and antibody responses: the case for convalescent plasma therapy. J Clin Invest 2020;130:5112-4. 10.1172/JCI139760. - DOI - PMC - PubMed
    1. Rojas M, Rodríguez Y, Monsalve DM, et al. Convalescent plasma in Covid-19: Possible mechanisms of action. Autoimmun Rev 2020;19:102554. 10.1016/j.autrev.2020.102554 - DOI - PMC - PubMed
    1. Luke TC, Casadevall A, Watowich SJ, Hoffman SL, Beigel JH, Burgess TH. Hark back: passive immunotherapy for influenza and other serious infections. Crit Care Med 2010;38(Suppl):e66-73. 10.1097/CCM.0b013e3181d44c1e - DOI - PubMed
    1. van Griensven J, Edwards T, de Lamballerie X, et al. Ebola-Tx Consortium Evaluation of Convalescent Plasma for Ebola Virus Disease in Guinea. N Engl J Med 2016;374:33-42. 10.1056/NEJMoa1511812 - DOI - PMC - PubMed
    1. Cheng Y, Wong R, Soo YO, et al. Use of convalescent plasma therapy in SARS patients in Hong Kong. Eur J Clin Microbiol Infect Dis 2005;24:44-6. 10.1007/s10096-004-1271-9 - DOI - PMC - PubMed

Publication types